Fibroblast Growth Factor 2
"Fibroblast Growth Factor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).
| Descriptor ID |
D016222
|
| MeSH Number(s) |
D12.644.276.624.120 D12.776.467.624.120 D23.529.624.120
|
| Concept/Terms |
Fibroblast Growth Factor 2- Fibroblast Growth Factor 2
- Basic Fibroblast Growth Factor
- Class II Heparin-Binding Growth Factor
- Heparin-Binding Growth Factor Class II
- HBGF-2
- Prostatropin
- FGF-2
- FGF 2
- FGF2
- Fibroblast Growth Factor, Basic
- Fibroblast Growth Factor-2
- Cartilage-Derived Growth Factor
- Cartilage Derived Growth Factor
- Prostate Epithelial Cell Growth Factor
|
Below are MeSH descriptors whose meaning is more general than "Fibroblast Growth Factor 2".
Below are MeSH descriptors whose meaning is more specific than "Fibroblast Growth Factor 2".
This graph shows the total number of publications written about "Fibroblast Growth Factor 2" by people in this website by year, and whether "Fibroblast Growth Factor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibroblast Growth Factor 2" by people in Profiles.
-
Comparison of Four Protocols for In Vitro Differentiation of Human Embryonic Stem Cells into Trophoblast Lineages by BMP4 and Dual Inhibition of Activin/Nodal and FGF2 Signaling. Reprod Sci. 2024 01; 31(1):173-189.
-
Feeding role of mouse embryonic fibroblast cells is influenced by genetic background, cell passage and day of isolation. Zygote. 2022 Aug; 30(4):550-560.
-
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018 03 05; 215(3):895-910.
-
Infusion of Valproic Acid Into the Renal Medulla Activates Stem Cell Population and Attenuates Salt-Sensitive Hypertension in Dahl S Rats. Cell Physiol Biochem. 2017; 42(3):1264-1273.
-
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo. Oncotarget. 2017 Jan 24; 8(4):5874-5884.
-
Improved Angiogenesis in Response to Localized Delivery of Macrophage-Recruiting Molecules. PLoS One. 2015; 10(7):e0131643.
-
Simultaneous in?vivo imaging of blood and lymphatic vessel growth in Prox1-GFP/Flk1::myr-mCherry mice. FEBS J. 2015 Apr; 282(8):1458-1467.
-
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12.
-
API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014 Jul 01; 74(13):3556-66.
-
ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.